SCHEMBL3666014

SCHEMBL3666014

Cc1cccc(NC(=O)Nc2cccc(-c3c(-c4ccc5[nH]nc(N)c5c4)nnn3Cc3ccccc3)c2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 19/20 0.67
MAP4K4 O95819 9/20 0.67
PRKACA P17612 9/20 0.67
GSK3B P49841 9/20 0.67
CLK4 Q9HAZ1 8/20 0.67
ROCK2 O75116 8/20 0.67
CDK2 P24941 7/20 0.67
PRKD3 O94806 7/20 0.67
CLK2 P49760 7/20 0.67
CDK5 Q00535 7/20 0.67
MAP4K2 Q12851 7/20 0.67
ROCK1 Q13464 7/20 0.67
DYRK1A Q13627 7/20 0.67
AURKB Q96GD4 7/20 0.67
MKNK2 Q9HBH9 7/20 0.67
DAPK3 O43293 6/20 0.67
GSK3A P49840 6/20 0.67
PRKX P51817 6/20 0.67
JAK3 P52333 6/20 0.67
RPS6KA3 P51812 6/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3670991 0.90 CDC7 (0.72) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3669350 0.85 CDC7 (0.70) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL16241480 0.84 CDC7 (0.67) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3666165 0.82 CDC7 (0.75) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL4285130 0.82 CDC7 (1.00) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3670770 0.81 CDC7 (0.77) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3672020 0.81 CDC7 (0.83) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3667673 0.80 CDC7 (0.70) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL27810147 0.80 CDC7 (0.70) CDC7MAP4K4PRKACAGSK3BCLK4
SCHEMBL3635048 0.80 CDC7 (0.86) CDC7MAP4K4PRKACAGSK3BCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885MAP4K4 51/4885PRKACA 178/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885MAP4K4 51/4885PRKACA 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.